## Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)

NTM-PD is becoming an increasingly prevalent disease in the United States and in many places in the world.

How do you recognize and diagnose it? What are the basic tenets of treatment?



© 2021 American College of Chest Physicians

#### CLINICAL PRESENTATION



Fever



Weight

Loss



Cough

↑ Sputum



Shortness of Breath

ATS/ERS/ESCMID/IDSA Diagnostic Criteria<sup>2</sup> (All three criteria required and exclusion of alternative diagnosis)



#### **Clinical Features**

Pulmonary or systemic symptoms (as above)



### **Radiographic Changes**

Nodular or cavitary lung opacities on chest imaging, or

Chest CT showing bronchiectasis with multiple small nodules (tree-in-bud appearance)



### Microbiology

Positive sputum culture results from >2 samples,

#### or

Positive bronchial wash or BAL culture,  $\underline{\text{or}}$ 

Transbronchial/lung biopsy with mycobacterial histologic features and positive culture for NTM,

#### <u>or</u>

Biopsy showing mycobacterial histologic features and >1 sputum or bronchial culture positive for NTM

McShane PJ, Glassroth J. Pulmonary disease due to NTM: current state and new insights.


<sup>2</sup> Daley CL, laccarino JM, Lange C, etc. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. *Eur Respir J*. 2020.

## Radiographic Patterns or Clinical Phenotypes<sup>1</sup>




### Fibronodular Bronchiectasis (Often in post-menopausal women)

- Nodular and small centrilobular nodules or tree-in-bud opacities
- Bronchiectasis with right middle lobe and lingular predominance



# Fibrocavitary (Often coexisting emphysema in men)

- Upper lobe predominant cavitation
- Adjacent ground glass +/micronodules



## Hypersensitivity Pneumonitis ("Hot tub lung")

- Diffuse ill-defined centrilobular nodules with ground glass
- Associated with inhalation exposure (eg, MAC from hot tub)

## Treatment Pearls for M. Avium Complex (MAC) Lung Disease<sup>2</sup>

- Typically includes a three-drug regimen based on drug-susceptibilities for macrolide and amikacin; consider consultation with specialist
- Duration: At least 12 months after sputum culture conversion
  - Macrolide (Azithromycin preferred) + Rifamycin + Ethambutol
  - Cavitary/severe disease/macrolide-resistance → add IV amikacin or streptomycin and daily oral antimicrobial therapy
  - No response after treatment for 6 months (probable refractory MAC lung disease) → consider adding inhaled liposomal amikacin